Characterization of the 'estrogenicity' of tamoxifen and raloxifene in HepG2 cells: Regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes

Journal of Steroid Biochemistry and Molecular Biology

Volumn 62, Issue 1, 1997, Pages 53-64

  Barkhem, Tomas ^a   Andersson Ross, Christina ^a   Höglund, Marie ^a   Nilsson, Stefan ^a  

^a Karo Bio   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; INTERLEUKIN 1BETA; MOXESTROL; RALOXIFENE; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN;

ARTICLE; CARCINOMA CELL; CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; REPORTER GENE;

ALKALINE PHOSPHATASE; CARCINOMA, HEPATOCELLULAR; CLONE CELLS; ESTRADIOL; ESTRADIOL CONGENERS; ESTROGEN ANTAGONISTS; ETHINYL ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; KINETICS; LIVER NEOPLASMS; PIPERIDINES; PLACENTA; PREGNANCY; PROTEIN BIOSYNTHESIS; PROTEINS; RALOXIFENE; RECEPTORS, ESTROGEN; RECOMBINANT FUSION PROTEINS; SEX HORMONE-BINDING GLOBULIN; TAMOXIFEN; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0030731796     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(97)00017-4     Document Type: Article

References (68)

1. Evans R. M.: The steroid and thyroid hormone receptor superfamily. Science 240 (1988) 889-895.
2. Gronemeyer H. and Laudet V.: Transcription factors 3: nuclear receptors. Protein Profile 2 (1995) 1167-1322.
3. Beato M.: Gene regulation by steroid hormones. Cell 56 (1989) 335-344.
4. Gronemeyer H.: Control of transcription activation by steroid hormone receptors. FASEB J. 6 (1992) 2524-2529.
5. Green S. and Chambon P.: Nuclear receptors enhance our understanding of transcription regulation. Trends Genet. 4 (1988) 309-314.
6. Haynes, R. C., Murad, F., Kuret, J. A. and Wilson, J. D.: Hormones and hormone antagonists. In The Pharmacological Basis of Therapeutics, 8th edn, eds A. Goodman Gilman, T. W. Rall, A. S. Nies and P. Taylor. Pergamon Press, New York, 1990, pp. 1332, 1361-1462, 1510-1522.
7. Nilsson, S. and Norinder, U.: Computer assisted drug design and biotechnology: a case study on lead optimization related to breast cancer therapy. In Bioactive Compound Design: Possibilities for Industrial Use, eds M. G. Ford, R. Greenwood, G. T. Brooks and R. Franke. BIOS Scientific Publishers Ltd, Oxford, 1996, pp. 109-118.
8. Katzenellenbogen J. A., O'Malley B. W. and Katzenellenbogen B. S.: Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Molec. Endocr. 10 (1996) 119-131.
9. Allan G. F., Leng X., Tsai S. Y., Weigel N. L., Edwards D. P., Tsai M.-J. and O'Malley B. W.: Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J. Biol. Chem. 267 (1992) 19513-19520.
10. Beekman J. M., Allan G. F., Tsai S. Y., Tsai M.-J. and O'Malley B. W.: Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Molec. Endocr. 7 (1993) 1266-1274.
11. Berry M., Metzger D. and Chambon P.: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the antioestrogen 4-hydroxytamoxifen. EMBO J. 9 (1990) 2811-2818.
12. Tzukerman M. T., Esty A., Santiso-Mere D., Danielian P., Parker M. G., Stein R. B., Pike J. W. and McDonnell D. P.: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Molec. Endocr. 8 (1994) 21-30.
13. Montano M. M., Müller V., Trobaugh A. and Katzenellenbogen B. S.: The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Molec. Endocr. 9 (1995) 814-825.
14. McDonnell D. P., Clemm D. L., Hermann T., Goldman M. E. and Pike J. W.: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Molec. Endocr. 9 (1995) 659-669.
15. Montano M. M., Ekena K., Krueger K. D., Keller A. L. and Katzenellenbogen B. S.: Human estrogen receptor activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Molec. Endocr. 10 (1996) 230-242.
16. Umesono K. and Evans R. M.: Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57 (1989) 1139-1146.
17. Jonat C., Rahmsdorf H. J., Park K.-K., Cato A. C. B., Gebel S., Ponta H. and Herrlich P.: Antitumor promotion and antiinflammation: down-modulation of AP-1 fos/jun) activity by glucocorticoid hormone. Cell 62 (1990) 1189-1204.
18. Phal M.: Nuclear receptor/AP-1 interaction. Endocr. Rev. 14 (1993) 651-658.
19. Webb P., Lopez G. N., Uht R. M. and Kushner P.: Tamoxifen activation of the estrogen receptor /AP1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Molec. Endocr. 9 (1995) 443-456.
20. Ciocca D. R. and Vargas Roig L. M.: Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr. Rev. 16 (1995) 35-61.
21. Kuiper G. G. J. M., Enmark E., Pelto-Huikko M., Nilsson S. and Gustafsson J.-Å.: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5925-5930.
22. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339 (1992) 1-15.
23. Jordan V. C.: A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol 110 (1993) 507-517.
24. Fex G., Adielsson G. and Mattson W.: Oestrogen-like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocr. 97 (1981) 109-113.
25. Bagdade J. D., Wolter J., Subbaiah P. V. and Ryan W.: Effects of tamoxifen on plasma lipids and lipoprotein lipid composition. J. Clin. Endocr. Metab. 70 (1990) 1132-1135.
26. Love R. R., Wiebe D. A., Feyzi J. M., Newcomb P. A. and Chappell R. J.: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 86 (1994) 1534-1539.
27. McDonald C. C., Alexander F. E., Whyte B. W., Forrest A. P. and Stewart H. J.: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ 311 (1995) 977-980.
28. Nabulsi A. A., Folsom A. R., White A., Patsch W., Heiss G., Wu K. K. and Szklo M.: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N. Engl. J. Med. 328 (1993) 1069-1075.
29. Sakai F., Cheix F., Clavel M., Colon J., Mayer M., Pommatau E. and Saez S.: Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J. Endocr. 76 (1978) 219-226.
30. Bruning P. F., Bonfrer J. M. G., Hart A. A. M., de Jong-Bakker M., Linders D., van Loon J. and Nooyen W. J.: Tamoxifen, serum lipoproteins and cardiovascular risk. Br. J. Cancer 58 (1988) 497-499.
31. Powles T. J., Hardy J. R., Ashley S. E., Farrington G. M., Cosgrove D., Davey J. B., Dowsett M., McKinna J. A., Nash A. G., Sinnett H. D., Tillyer C. R. and Treleaven J. G.: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer 60 (1989) 126-131.
32. McDonnell D. P., Vegeto E. and Gleeson M. A. G.: Nuclear hormone receptors as targets for new drug discovery. Bio/Technology 11 (1993) 1256-1261.
33. Nilsson, S., Alksnis, M. and Ahola, H.: The use of engineered cells for evaluation of the activity of small organic compounds interacting with the human glucocorticoid receptor. In Proc. of the 5th Symp. on the Analysis of Steroids, ed. S. Görög. Akadémiai Kiadó, Budapest, 1993, p. 57.
34. Alam J. and Cook J. L.: Reporter genes: application to the study of mammalian gene transcription. Analyt. Biochem. 188 (1990) 245-254.
35. Jones C. D., Jevnikar M. G., Pike A. J., Peters M. K., Black L. J., Thompson A. R., Falcone J. F. and Clemens J. A.: Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]- phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 27 (1984) 1057-1066.
36. Klein-Hitpaß L., Schorrp M., Wagner U. and Ryffel G. U.: An estrogen-responsive element derived from the 5′ flanking region of the xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46 (1986) 1053-1061.
37. Brüggemeier U., Rogge L., Winnacker E.-L. and Beato M.: Nuclear factor I acts as a transcription factor on the MMTV promoter but competes with steroid hormone receptors for DNA binding. EMBO J. 9 (1990) 2233-2239.
38. Berger J., Hauber J., Hauber R., Geiger R. and Cullen B. R.: Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 66 (1988) 1-10.
39. Alksnis M., Barkhem T., Strömstedt P.-E., Ahola H., Kutoh E., Gustafsson J.-Å., Poellinger L. and Nilsson S.: High level expression of functional full length and truncated glucocorticoid receptor in Chinese hamster ovary cells. J. Biol. Chem. 266 (1991) 10078-10085.
40. Black L. J., Sato M., Rowley E. R., Magee D. E., Bekele A., Williams D. C., Cullinan G. J., Bendele R., Kauffman R. F., Bensch W. R., Frolik C. A., Termine J. D. and Bryant H. U.: Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93 (1994) 63-69.
41. Andersson D. C.: Sex hormone binding globulin. Clin. Endocr. 3 (1974) 69-96.
42. Mercier-Bodard C., Baville F., Bideux G., Binart N., Chambraud B. and Baulieu E.-E.: Regulation of SBP synthesis in human cancer cell lines by steroid and thyroid hormones. J. Steroid. Biochem. 34 (1989) 199-204.
43. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A. Chambon P.: Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucl. Acids Res. 24 (1982) 7895-7903.
44. Poulsom R. and Wright N. A.: Trefoil peptides: a newly recognized family of epithelial mucin-associated molecules. Am. J. Physiol. 265 (1993) G205-G213.
45. Hammond G. L., Undehill D A., Rykse H. M. and Smith C. L.: The sex hormone-binding globulin gene contains exons for androgen-binding protein and two other testicular messenger RNAs. Molec. Endocr. 3 (1989) 1869-1876.
46. Nunez A.-M., Berry M., Imler J.-L. and Chambon P.: The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J. 8 (1989) 823-829.
47. Jordan V. C., Parker C. J. and Morrow M.: Update: breast cancer treatment and prevention with antiestrogens in the 1990s. Endocr. Rev. 1 (1993) 82-85.
48. Powles T. J., Jones A. L., Ashley S. E., ÓBrien M. E. R., Tidy V. A., Treleaven J., Cosgrove D., Nash A. G., Sacks N., Baum M., McKinna J. A. and Davey J. B.: The Royal Marsden Hospital pilot tamoxifen chernoprevention trial. Breast Cancer Res. Treat. 31 (1994) 73-82.
49. Jordan V. C. and Murphy C. S.: Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev. 11 (1990) 578-610.
50. Toko T., Sugimoto Y., Matsuo K.-I., Yamasaki R., Takeda S., Wierzba K., asao T. and Yamada Y.: TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors. Eur. J. Cancer 26 (1990) 397-404.
51. Chander S. K., McCague R., Luqmani Y., Newton C., Dowsett M., Jarman M. and Coombes R. C.: Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res. 51 (1991) 5851-5858.
52. Bruning P. F.: Droloxifene, a new antiestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur. J. Cancer 28A (1992) 1404-1407.
53. DeFriend D. J., Howell A., Nicholson R. I., Anderson E., Dowsett M., Mansel R. E., Blamey R. W., Bundred N. J., Robertson J. F., Saunders C., Baum M., Walton P., Sutcliffe F. and Wakeling A. E.: Investigation of a new pure antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res. 54 (1994) 414-498.
54. Korach, K. S., Migliaccio, S. and Davis, V. L.: Estrogens. In Principles of Pharmacology, eds P. L. Munson, R. A. Mueller and G. R. Breese). Chapman and Hall, International Thomson Publishing Inc., New York, 1995, pp. 809, 818-820.
55. Kedar R. P., Bourne T. H., Powles T. J., Collins W. P., Ashley S. E., Cosgrove D. O. and Campbell S.: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343 (1994) 1318-1321.
56. Fornander T., Cedermark B., Mattsson A., Skoog L., Theve T., Askergren J., Rutqvist L. E., Glas U., Silfverswärd C., Somell A., Wilking N. and Hjalmar M. L.: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 (1989) 117-120.
57. Love R. R., Wiebe D. A., Newcomb P. A., Cameron L., Leventhal H., Jordan V. C., Feyzi J. and DeMets D. L.: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Intern. Med. 115 (1991) 860-864.
58. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E. and Chambon P.: The human estrogen receptor has two independent transcriptional activation functions. Cell 59 (1989) 477-487.
59. Weaver C. A., Springer P. A. and Katzenellenbogen B. S.: Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells. Molec. Endocr. 2 (1988) 936-945.
60. Roberts M., Wallace J., Jeltsch J.-M. and Berry M.: The 5′ flanking region of the human pS2 gene mediates its transcriptional activation by estrogen in MCF-7 cells. Biochem. Biophys. Res. Commun. 151 (1988) 306-313.
61. Zajchowski D. A. and Sager R.: Induction of estrogen-regulated genes differ in immortal and tumorigenic human mammary epithelial cells expressing a recombinant estrogen receptor. Molec. Endocr. 5 (1991) 1613-1623.
62. Archer T. K., Zaniewski E., Moyer M. L. and Nordeen S. K.: The differential capacity of glucocorticoids and progestins to alter chromatin structure and induce gene expression in human breast cancer cells. Molec. Endocr. 8 (1994) 1154-1162.
63. Powles T. J., Tillyer C. R., Jones A. L., Ashley S. E., Treleaven J., Davey J. B. and McKinna J. A.: Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital programme. Eur. J. Cancer 26 (1990) 680-684.
64. Powis G.: Anticancer drugs acting against signaling pathways. Curr. Opin. Oncol. 7 (1995) 554-559.
65. Wiseman H.: Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol. Sci. 15 (1994) 83-89.
66. Mercier-Bodard C., Nivet V. and Baulieu E.-E.: Effects of hormones on SBP mRNA levels in human cancer cells. J. Steroid Biochem. Molec. Biol. 40 (1991) 777-785.
67. Lapidus L., Lindstedt G., Lundberg P.-A., Bengtsson C. and Gredmark T.: Concentrations of sex-hormone binding globulin and corticoidsteroid binding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women. Clin. Chem. 32 (1986) 146-152.
68. Freiss G. and Vignon F.: Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Molec. Endocr. 8 (1994) 1389-1396.